Previous 10 | Next 10 |
The pharmaceutical sector received much investor attention amid the COVID-19 pandemic and their interest in this sector is expected to continue given the growing demand for pharmaceutical products and solutions. As such, we think it could be smart to bet on relatively undervalued pharma stock...
Ironwood Pharmaceuticals (IRWD) announced that the company with its partner AbbVie has reached an agreement with Teva Pharmaceuticals (TEVA) in granting a license related to a generic version of constipation med LINZESS (linaclotide).With the license for its abbreviated new drug applicat...
– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today that, with its partner AbbVie Inc., the companies have reached an agreement with T...
– Ironwood also presented results of a separate survey of nearly 90,000 Americans that highlights the prevalence and burden of multiple GI diseases – – Preclinical data presented at DDW highlight linaclotide’s effect on visceral hypersensitivity, wh...
– Presentations feature four posters of distinction – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present seven posters – four of which have been named pos...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2021 Earnings Conference Call May 06, 2021, 08:30 ET Company Participants Meredith Kaya - VP, IR & Corporate Communications Thomas McCourt - President & Interim CEO Gina Consylman - Principal Accounting Officer, CFO, SVP & Treasurer Michael...
Image source: The Motley Fool. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q1 2021 Earnings Call May 6, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals Inc (IRWD) Q1 2021 Earnings Call Trans...
Ironwood Pharmaceuticals (IRWD) has authorized a share buyback program of up to $150M through December 2022.Ironwood shares are unchanged in premarket trading at $10.83. For further details see: Ironwood Pharmaceuticals announces $150M share buyback
Ironwood Pharmaceuticals (IRWD): Q1 Non-GAAP EPS of $0.24 beats by $0.03; GAAP EPS of $0.25 in-line.Revenue of $88.85M (+11.1% Y/Y) misses by $2.3M.FY 2021 Guidance: U.S. LINZESS Net Sales Growth of 3% to 5%; Total Revenue of $370M-385M vs. consensus of $388.53M; Adjusted EBITD...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...